Synthesis and structure–activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis

The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel present in the membrane of epithelial cells. Mutations affecting the CFTR gene cause cystic fibrosis (CF), a multi-organ severe disease. The most common CF mutation, F508del, impairs the processing and activity (gati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medicinal chemistry 2015-06, Vol.99, p.14-35
Hauptverfasser: Pesce, Emanuela, Bellotti, Marta, Liessi, Nara, Guariento, Sara, Damonte, Gianluca, Cichero, Elena, Galatini, Andrea, Salis, Annalisa, Gianotti, Ambra, Pedemonte, Nicoletta, Zegarra-Moran, Olga, Fossa, Paola, Galietta, Luis J.V., Millo, Enrico
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel present in the membrane of epithelial cells. Mutations affecting the CFTR gene cause cystic fibrosis (CF), a multi-organ severe disease. The most common CF mutation, F508del, impairs the processing and activity (gating) of CFTR protein. Other mutations, like G551D, only cause a gating defect. Processing and gating defects can be targeted by small molecules called generically correctors and potentiators, respectively. Aminoarylthiazoles (AATs) represent an interesting class of compounds that includes molecules with dual activity, as correctors and potentiators. With the aim to improve the activity profile of AATs, we have now designed and synthesized a library of novel compounds in order to establish an initial SAR that may provide indications about the chemical groups that are beneficial or detrimental for rescue activity. The new compounds were tested as correctors and potentiators in CFBE41o-expressing F508del-CFTR using a functional assay. A dual active compound, AAT-4a, characterized by improved efficacy and marked synergy when combined with the corrector VX-809 has been identified. Moreover, by computational methods, a possible binding site for AATs in nucleotide binding domain NBD1 has been detected. These results will direct the synthesis of new analogues with possibly improved activity. Synthesis and evaluation of novel aminoarylthiazoles carrying different substitutions at positions 2, 4, and 5 of the thiazole ring identifies a compounds with dual rescue activity on mutant CFTR channel. [Display omitted] •We synthesized a high number of aminoarylthiazoles(AATs) variously substituted.•The range of activities allowed us to construct a plausible SAR.•Compounds are active as correctors with an interest in the therapy of cystic fibrosis.•Docking simulations using a 3D model of the wt-CFTR protein suggest a possible binding site.
ISSN:0223-5234
1768-3254
DOI:10.1016/j.ejmech.2015.05.030